Hims & Hers Health Balance Sheet Health
Financial Health criteria checks 5/6
Hims & Hers Health has a total shareholder equity of $562.7M and total debt of $969.5M, which brings its debt-to-equity ratio to 172.3%. Its total assets and total liabilities are $1.9B and $1.3B respectively. Hims & Hers Health's EBIT is $131.0M making its interest coverage ratio -9.3. It has cash and short-term investments of $1.1B.
Key information
172.29%
Debt to equity ratio
US$969.47m
Debt
| Interest coverage ratio | -9.3x |
| Cash | US$1.14b |
| Equity | US$562.70m |
| Total liabilities | US$1.31b |
| Total assets | US$1.88b |
Recent financial health updates
No updates
Recent updates
Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S Is Still On The Mark Following 33% Share Price Bounce
Sep 27
Hims & Hers: Navigating GLP Controversy With Aplomb, But Risks Warrant Hold Rating
Sep 26What You Can Learn From Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S After Its 26% Share Price Crash
Jul 22📈 HIMS' Asymmetric Opportunity, JIN’s Overlooked Strengths, and PROX's Possible Re-Rating
May 21
Hims: The Platform Powering Personalised Healthcare
Platform Play, Not a Pill Company: Hims is building the infrastructure for personalised, direct-to-consumer healthcare across diagnostics, treatment, and prevention, similar to what Amazon did for retHims & Hers Health's (NYSE:HIMS) Performance Is Even Better Than Its Earnings Suggest
May 13After Leaping 89% Hims & Hers Health, Inc. (NYSE:HIMS) Shares Are Not Flying Under The Radar
May 08Hims & Hers Health: GLP-1 Deals De-Risk The Story
Apr 29Hims & Hers: Look Past Near-Term GLP-1 Risks, This Is A Great Dip To Buy
Apr 23With A 29% Price Drop For Hims & Hers Health, Inc. (NYSE:HIMS) You'll Still Get What You Pay For
Mar 24Hims & Hers Has Superstar Potential, But It Will Take A Lot To Get There
Mar 20Hims & Hers' Fall From Grace Is Warranted - Still No Margin Of Safety
Mar 03Hims & Hers: Why This Q4 Earnings Dip Is A Buying Opportunity
Feb 25Hims & Hers Q4 Preview: Is The Super Bowl Ad Worth $5B In Market Cap? (Rating Downgrade)
Feb 19Hims & Hers Health: Explosive Growth Potential Ahead
Feb 11Market Participants Recognise Hims & Hers Health, Inc.'s (NYSE:HIMS) Revenues Pushing Shares 46% Higher
Feb 04Hims & Hers: Potential Risks Ahead, But Shorting May Be Premature
Jan 29Hims & Hers Health: The Market Is Likely Wrong
Jan 19Don't Buy Hims & Hers Stock If You Want Better Than Mediocre Returns
Jan 09Hims & Hers: Ready For Liftoff In 2025
Jan 02Hims & Hers: FDA Ruling May Close Compounded GLP-1 Drug 'Loophole', It Was Fun While It Lasted
Dec 19Hims & Hers: Look At What Matters Most
Dec 12Hims & Hers: The Show Must Go On
Dec 05Hims & Hers: Driving Growth In Wellness
Nov 29Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 44% Share Price Surge
Nov 26Hims & Hers Health: The Amazon Curse Is Being Overstated
Nov 15Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow
Nov 05Financial Position Analysis
Short Term Liabilities: HIMS's short term assets ($1.4B) exceed its short term liabilities ($272.2M).
Long Term Liabilities: HIMS's short term assets ($1.4B) exceed its long term liabilities ($1.0B).
Debt to Equity History and Analysis
Debt Level: HIMS has more cash than its total debt.
Reducing Debt: HIMS's debt to equity ratio has increased from 0% to 172.3% over the past 5 years.
Debt Coverage: HIMS's debt is well covered by operating cash flow (27%).
Interest Coverage: HIMS earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/28 15:12 |
| End of Day Share Price | 2025/09/26 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hims & Hers Health, Inc. is covered by 21 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vikram Kesavabhotla | Baird |
| Allen Lutz | BofA Global Research |
| Allen Lutz | BofA Global Research |